These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 33913511

  • 1. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB.
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [Abstract] [Full Text] [Related]

  • 2. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L, EXCEED Study Group.
    Lancet; 2020 May 09; 395(10235):1496-1505. PubMed ID: 32386593
    [Abstract] [Full Text] [Related]

  • 3. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.
    J Drugs Dermatol; 2015 Aug 09; 14(8):821-33. PubMed ID: 26267726
    [Abstract] [Full Text] [Related]

  • 4. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D.
    Br J Dermatol; 2022 Jun 09; 186(6):942-954. PubMed ID: 34981829
    [Abstract] [Full Text] [Related]

  • 5. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.
    Br J Dermatol; 2020 Jun 09; 182(6):1348-1358. PubMed ID: 31887225
    [Abstract] [Full Text] [Related]

  • 6. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P.
    Ann Rheum Dis; 2020 Oct 09; 79(10):1310-1319. PubMed ID: 32660977
    [Abstract] [Full Text] [Related]

  • 7. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R.
    Br J Dermatol; 2020 Feb 09; 182(2):304-315. PubMed ID: 31102257
    [Abstract] [Full Text] [Related]

  • 8. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M.
    Br J Dermatol; 2023 Feb 22; 188(3):330-340. PubMed ID: 36751950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF.
    J Dermatol; 2019 Sep 07; 46(9):752-758. PubMed ID: 31342560
    [Abstract] [Full Text] [Related]

  • 12. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB, Barker JNWB, Finlay AY, Burden AD, Kirby B, Armendariz Y, Williams R, Hatchard C, Khare S, Griffiths CEM.
    Br J Dermatol; 2020 Jul 07; 183(1):60-70. PubMed ID: 31628677
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, PSUMMIT 2 Study Group.
    Ann Rheum Dis; 2014 Jun 07; 73(6):990-9. PubMed ID: 24482301
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb 07; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb 07; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments.
    Wang Y, Xiao Y, Zhang L, Li F, Hu H, Peng X, Gao J, Yang M, Yan W, Qiu L, Li W.
    J Dermatolog Treat; 2024 Dec 07; 35(1):2411849. PubMed ID: 39370135
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 07; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J.
    Adv Ther; 2022 Jan 07; 39(1):583-597. PubMed ID: 34816373
    [Abstract] [Full Text] [Related]

  • 20. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
    Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM.
    Dermatology; 2022 Jan 07; 238(4):620-629. PubMed ID: 34823247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.